Myrtelle

Myrtelle Myrtelle Inc. When not broken down by oligodendrocytes, NAA accumulates in the brain and disrupts the normal bioenergetics, myelin production, and brain health.

is a gene therapy company focused on providing hope and progress by developing transformative treatments for neurodegenerative diseases that affect patients who have few, if any, treatment options. Our lead program is a novel investigational gene therapy treatment for Canavan disease (CD), a fatal genetic brain disorder in which mutations in the ASPA gene prevent the normal expression of Aspartoac

ylase, a critical enzyme produced in oligodendrocyte cells that breaks down the neurochemical N-Acetylaspartic Acid (NAA). CD patients are affected at birth but may appear normal until several months, when symptoms begin to develop. Poor head control, abnormally large head size, eye tracking difficulty, excessive irritability, severely diminished muscle tone, and delays in reaching motor milestones such as rolling, sitting, and walking are typical. As the disease progresses, seizures, spasticity, difficulties in swallowing, and overall muscle deterioration emerge, with most affected children developing life-threatening complications by ten years of age. Currently, there is no cure for CD and only palliative treatments are available. Myrtelle’s social media channels are places for community members to connect and learn about Myrtelle’s initiatives. Discussion of medical and health topics should never be construed as medical advice. Contact a healthcare professional in your area for personal medical advice. Myrtelle does not represent that the information on our social media channels is accurate, complete, reliable, useful, timely, or current and Myrtelle does not undertake an obligation to update any such information. Myrtelle does not endorse any opinions or statements expressed by others on our social media channels. Myrtelle does not expressly endorse opinions or statements expressed by individuals, businesses, or channels we may ‘follow’, ‘like’, or ‘share’. At times, Myrtelle may link to external websites. Myrtelle is not responsible for the content or policies of these websites. Content submitted to our social media channels is public and will not place Myrtelle under any obligation to you.

By targeting oligodendrocytes directly, our gene therapy restores neural pathways right where myelin production and heal...
09/01/2026

By targeting oligodendrocytes directly, our gene therapy restores neural pathways right where myelin production and healing actually begin.

Learn more at www.myrtellegtx.com

By targeting oligodendrocytes to restore myelin at the biological source, Myrtelle’s lead gene therapy candidate, MYR-10...
08/25/2026

By targeting oligodendrocytes to restore myelin at the biological source, Myrtelle’s lead gene therapy candidate, MYR-101, addresses the root cause of Canavan disease while laying the foundation for a broader platform across white matter disorders.

Read the full article at www.myrtellegtx.com

Behind every clinical milestone is a family whose strength drives us forward.By delivering gene replacement to oligodend...
08/20/2026

Behind every clinical milestone is a family whose strength drives us forward.
By delivering gene replacement to oligodendrocytes, we aim to restore myelin insulation and turn precision science into real progress.

Learn more at www.myrtellegtx.com

By targeting oligodendrocytes to restore myelin at the source, Myrtelle’s lead therapy addresses the root cause of Canav...
08/13/2026

By targeting oligodendrocytes to restore myelin at the source, Myrtelle’s lead therapy addresses the root cause of Canavan disease while opening new possibilities for broader white matter disorders.

Read the full newsletter at https://bit.ly/45l8VmX

When a genetic mutation strips away the myelin insulation that helps a child's brain connect with the world, the silence...
07/23/2026

When a genetic mutation strips away the myelin insulation that helps a child's brain connect with the world, the silence can feel overwhelming, which is why at Myrtelle we pour our hearts into restoring that vital communication and giving families their voices back.

Read more at www.myrtellegtx.com

By targeting the biological root cause of Canavan disease, precision gene therapy is rewriting a future once told in sil...
07/14/2026

By targeting the biological root cause of Canavan disease, precision gene therapy is rewriting a future once told in silence and giving families an enduring reason to hope.

Read more at www.myrtellegtx.com

While data points and statistics are essential for regulatory progress, the most meaningful milestones in gene therapy a...
07/09/2026

While data points and statistics are essential for regulatory progress, the most meaningful milestones in gene therapy are the ones that transform daily life for children and their families.

Read more: https://myrtellegtx.com/beyond-the-biomarkers/

At ASGCT 2026, groundbreaking data proved that a single gene therapy dose achieved persistent cassette detection 15 year...
07/07/2026

At ASGCT 2026, groundbreaking data
proved that a single gene therapy dose achieved
persistent cassette detection 15 years after transfer,
a milestone honoring the early families who chose
hope.

Read more at https://bit.ly/4gS1OsW

Myrtelle’s historic data at ASGCT 2026 proves a single gene therapy dose remains detectable 15 years later, validating t...
06/30/2026

Myrtelle’s historic data at ASGCT 2026 proves a single gene therapy dose remains detectable 15 years later, validating the durable potential of our myelin-targeting platform.

Read more: https://myrtellegtx.com/news/

Address

Wakefield, MA
01880

Alerts

Be the first to know and let us send you an email when Myrtelle posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share